Edgewise Therapeutics, a biopharmaceutical company, has recently released its 10-K report. The company, founded in 2017 and headquartered in Boulder, Colorado, focuses on discovering, developing, and commercializing therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, is an orally administered small molecule in Phase II clinical trials designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. Additionally, the company is developing EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders, which is in Phase I clinical trials.
In the 10-K report, under Item 7, "Management’s Discussion and Analysis of Financial Condition and Results of Operations," Edgewise Therapeutics reported significant losses since its inception. The net losses were $167.8 million and $133.8 million for the years ended December 31, 2025, and 2024, respectively. As of December 31, 2025, the company had an accumulated deficit of $546.4 million. Edgewise Therapeutics has primarily financed its operations through private placements of convertible preferred stock and public offerings of its common stock, generating net proceeds of $793.7 million as of December 31, 2025. The company believes that its existing cash and cash equivalents, along with marketable securities of $530.1 million, will enable it to fund planned operating expenses and capital expenditure requirements for at least the next 12 months.
The report also discusses the company's monitoring of macroeconomic and geopolitical developments, such as inflation, public health pandemics, and changes in tariffs, and their potential impacts on its operations, clinical development timelines, supply chain continuity, and capital markets access.
Furthermore, the report provides a detailed breakdown of the components of the company's results of operations. Operating expenses primarily consist of research and development activities and general and administrative functions that support clinical programs and corporate infrastructure. Research and development expenses, which totaled $151.4 million in 2025, include costs incurred in connection with the discovery and development of product candidates, such as employee and external consultant-related expenses, external expenses for clinical development, and preclinical development expenses.
The report also includes a comparison of the company's results of operations for the years ended December 31, 2025, and 2024. In 2025, Edgewise Therapeutics reported a net loss of $167.8 million, compared to a net loss of $133.8 million in 2024. The research and development expenses for 2025 amounted to $151.4 million, representing an increase of $24.4 million compared to 2024. The increase was attributed to higher clinical program expenses, particularly in the sevasemten clinical program.
Today the company's shares have moved 2.97% to a price of $27.39. If you want to know more, read the company's complete 10-K report here.
